Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain

Last updated: June 4, 2015
Sponsor: Bracco Diagnostics, Inc
Overall Status: Completed

Phase

4

Condition

Neurologic Disorders

Treatment

N/A

Clinical Study ID

NCT01613417
PH-107
  • Ages > 18
  • All Genders

Study Summary

This study aims at a direct comparison between ProHance (0.1 mmol/kg) and a validated comparator Gadovist/Gadavist (0.1 mmol/kg) in a crossover intra-individual design in subjects with brain tumors to confirm the identical overall technical and diagnostic performance of the two MR contrast agents.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Are scheduled to undergo MRI

  • Are willing to undergo two MRI procedures within 14 days

  • Have confirmed or are highly suspected of brain disease likely to enhance asdetermined by the following:

  • Clinical/neurological symptomatology;

  • Diagnostic testing, such as CT or previous MRI examinations; or

  • Have had previous brain surgery and are to be evaluated for recurrence.

Exclusion

Exclusion Criteria:

  • Are pregnant or lactating females. Exclude the possibility of pregnancy:

  • by testing on site at the institution within 24 hours prior to the start of eachinvestigational product administration; or

  • by history (i.e., tubal ligation or hysterectomy); or

  • post menopausal with a minimum of 1 year without menses

  • Have any known allergy to one or more of the ingredients in the investigationalproducts, or have a history of hypersensitivity to any metals

  • Have congestive heart failure (class IV according to the classification of the NewYork Heart Association; see Appendix A)

  • Have suffered a stroke within a year

  • Have received or are scheduled to receive any other contrast medium in the 24 hourspreceding through the 24 hours following Exam 1, and in the 24 hours preceding throughthe 24 hours following Exam 2

  • Have received or are scheduled to receive an investigational compound and/or medicaldevice within 30 days before admission into the present study, through the 24 hourspost-administration of the second investigational product.

  • Have moderate-to-severe renal impairment, defined as a GFR/eGFR < 45 mL/min.

  • Have been previously entered into this study

  • Have received or are scheduled for one of the following:

  • Surgery within three weeks prior to the first examination or between the twoexaminations

  • Initiation of steroid therapy between the two examinations

  • Radiosurgery between the two examinations

  • Have any contraindications to MRI such as a pace-maker, magnetic material (i.e.,surgical clips) or any other conditions that would preclude proximity to a strongmagnetic field.

  • Are suffering from severe claustrophobia

Study Design

Total Participants: 229
Study Start date:
August 01, 2012
Estimated Completion Date:
April 30, 2014

Study Description

Adult patients were given two MRI exams, one after injection of ProHance (0.1 mmol/kg) and one after injection of Gadovist/Gadavist (0.1 mmol/kg). The exams were performed with identical equipment and imaging parameters with the order of the two exams randomized and 2-14 days between the first and the second MRI exam. Image data was evaluated by 3 expert neuroradiologist blinded to the agent administered and patient clinical data.

Connect with a study center

  • Holy Name Medical Center

    Teaneck, New Jersey 07666
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.